Evidence map›Paper›PMID 27542280›Full record

ArticleOncotarget2016

The cytokine-cosmc signaling axis upregulates the tumor-associated carbohydrate antigen Tn.

Chia-Wen Ho, Chi-Yu Lin, Yi-Wei Liaw, Hsiao-Ling Chiang, Yu-Tang Chin, Rui-Lan Huang, Hung-Cheng Lai, Yaw-Wen Hsu, Po-Jan Kuo, Chiao-En Chen and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Chia-Wen HoCenter for Cancer Research, Taipei Medical University, Taipei, Taiwan.
Chi-Yu LinDepartment of Biochemistry, Medical College, Taipei Medical University, Taipei, Taiwan.
Yi-Wei LiawDepartment of Biochemistry, Medical College, Taipei Medical University, Taipei, Taiwan.
Hsiao-Ling ChiangDepartment of Biochemistry, Medical College, Taipei Medical University, Taipei, Taiwan.
Yu-Tang ChinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Rui-Lan HuangDepartment of Obstetrics and Gynecology, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Hung-Cheng LaiDepartment of Obstetrics and Gynecology, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Yaw-Wen HsuGraduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
Po-Jan KuoDepartment of Periodontology, School of Dentistry, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan.
Chiao-En ChenGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Hung-Yan LinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Jacqueline Whang-PengGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Shin NiehGraduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
Earl FuGraduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.
Leroy F LiuCenter for Cancer Research, Taipei Medical University, Taipei, Taiwan.
Jaulang HwangCenter for Cancer Research, Taipei Medical University, Taipei, Taiwan.
Taipei Medical University · TWNational Defense Medical Center · TWInstitute of Molecular Biology, Academia Sinica · TWTaipei Medical University-Shuang Ho Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tn antigen (GalNAc-α-O-Ser/Thr), a mucin-type O-linked glycan, is a well-established cell surface marker for tumors and its elevated levels have been correlated with cancer progression and prognosis. There are also reports that Tn is elevated in inflammatory tissues. However, the molecular mechanism for its elevated levels in cancer and inflammation is unclear. In the current studies, we have explored the possibility that cytokines may be one of the common regulatory molecules for elevated Tn levels in both cancer and inflammation. We showed that the Tn level is elevated by the conditioned media of HrasG12V-transformed-BEAS-2B cells. Similarly, the conditioned media obtained from LPS-stimulated monocytes also elevated Tn levels in primary human gingival fibroblasts, suggesting the involvement of cytokines and/or other soluble factors. Indeed, purified inflammatory cytokines such as TNF-α and IL-6 up-regulated Tn levels in gingival fibroblasts. Furthermore, TNF-α was shown to down-regulate the COSMC gene as evidenced by reduced levels of the COSMC mRNA and protein, as well as hypermethylation of the CpG islands of the COSMC gene promoter. Since Cosmc, a chaperone for T-synthase, is known to negatively regulate Tn levels, our results suggest elevated Tn levels in cancer and inflammation may be commonly regulated by the cytokine-Cosmc signaling axis.

Indexed as

Gene Expression Regulation, NeoplasticAntigens, Tumor-Associated, CarbohydrateBreast NeoplasmsBronchiCell LineCpG IslandsCulture Media, ConditionedDisease ProgressionDNA MethylationFemaleFibroblastsGenes, rasGingivaHumansInflammationInterleukin-6Antigens, Tumor-Associated, CarbohydrateC1GALT1C1 protein, humanCulture Media, ConditionedIL6 protein, humanInterleukin-6Molecular ChaperonesTn antigenTumor Necrosis Factor-alphacosmccytokineshypermethylationTn antigentumor-associated carbohydrate

Identifiers

PMID27542280
PMCPMC5308701
OpenAlexW2508020318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.